Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16565977 | 0.80 | PAX8 (0.35) | PAX8DPP4FAPDPP8DPP9 | |
| SCHEMBL12285003 | 0.78 | DPP4 (0.53) | PAX8DPP4FAPDPP8DPP9 | |
| SCHEMBL1034777 | 0.78 | DPP4 (0.53) | PAX8DPP4FAPDPP8DPP9 | |
| SCHEMBL23169746 | 0.78 | DPP4 (0.53) | PAX8DPP4FAPDPP8DPP9 | |
| SCHEMBL14151828 | 0.77 | DPP4 (0.50) | PAX8DPP4FAPDPP8DPP9 | |
| SCHEMBL1036161 | 0.77 | DPP4 (0.50) | PAX8DPP4FAPDPP8DPP9 | |
| SCHEMBL23543184 | 0.74 | MME (0.42) | — | |
| SCHEMBL12428127 | 0.72 | CTSC (0.41) | PAX8DPP4FAPDPP8DPP9 | |
| SCHEMBL17209389 | 0.72 | CTSC (0.41) | PAX8DPP4FAPDPP8DPP9 | |
| SCHEMBL29198632 | 0.71 | TGFBR1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | MABPLEX INTERNATIONAL CO., LTD (CN) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | DARS1, CD2, FCGR2A | PAX8 4082/4885DPP4 1658/4885FAP 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.